-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 24, 2021, AbbVie and Teneobio jointly announced that AbbVie will exercise its exclusive right to acquire TeneoOne, a subsidiary of Teneobio and its main product under development-targeting B cell mature antigen ( BCMA)'s bispecific antibody therapy TNB-383B
This acquisition is based on the results of an interim analysis of a Phase 1 clinical trial conducted in humans for the first time.
▲TNB-383B (picture source: Teneobio official website)
In terms of safety, the most common of all grades of adverse events observed after treatment were cytokine release syndrome (CRS) (52%), fatigue (25%) and neutropenia (24%)
Note: The original text has been deleted
Reference materials:
[1] AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma.